Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction

Background

Since soluble TRAIL exhibits anti-inflammatory and anti-atherosclerotic activities both in vitro and in animal models, this study was designed to assess the relationship between the serum levels of TRAIL and clinical outcomes in patients with acute myocardial infarction (AMI).

Methodology/Principal Findings

Levels of TRAIL were measured by ELISA in serial serum samples obtained from 60 patients admitted for AMI, both during hospitalization and in a follow-up of 12 months, as well as in 60 healthy control subjects. Serum levels of TRAIL were significantly decreased in patients with AMI at baseline (within 24 hours from admission), compared with healthy controls, and showed a significant inverse correlation with a series of negative prognostic markers, such as CK, CK-MB and BNP. TRAIL serum levels progressively increased at discharge, but normalized only at 6–12 months after AMI. Of note, low TRAIL levels at the patient discharge were associated with increased incidence of cardiac death and heart failure in the 12-month follow-up, even after adjustment for demographic and clinical risk parameters (hazard ratio [HR] of 0.93 [95% CI, 0.89 to 0.97]; p = 0.001).

Conclusions/Significance

Although the number of patients studied was limited, our findings indicate for the first time that circulating TRAIL might represent an important predictor of cardiovascular events, independent of conventional risk markers.     

心肌坏死标志物联合检测对急性心肌梗死早期诊断及鉴别的价值

目的:探讨心肌坏死标志物联合检测在急性心肌梗死早期诊断及鉴别中的意义。方法:选取2010年12月至2013年5月我院收治的90例患者,45例确诊急性心肌梗死患者为观察组,其余45例非急性心肌梗死患者为对照组。分别采集两组患者静脉血4 m L用于检验。采用免疫抑制法测定患者血清中肌酸激酶(CK)和肌酸激酶同工酶(CK-MB)含量,采用电化学发光法检测肌钙蛋白I(c Tn I)和肌红蛋白(MYO)含量。观察并比较不同时间点两组患者血清中CK、CK-MB、c TnⅠ及MYO含量的变化情况。结果:与对照组比较,观察组的血清CK、CK-MB、c TnⅠ及MYO的含量明显升高,其中CK及MYO升高最为显著,差异具有统计学意义(P0.05)。CK、CK-MB在发病3~6 h后快速升高,24 h达高峰;c TnⅠ前24 h与CK-MB同步,但维持时间较长;MYO在发病后1~2 h发生异常,12 h达峰值(P0.05)。结论:心肌坏死标志物联合检测可提高急性心肌梗死的检出率,有助于疾病的及时发现、诊断和治疗。     

急性心肌梗死患者血清Hcy、hs-CRP、Cys-C水平变化及临床意义

目的:评价心肌梗死患者血清同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)及胱抑素C(Cys-C)水平变化及临床意义。方法:对急性心肌梗死(AMI)组66例患者血清Hcy、hs-CRP、Cys-C水平进行测定,并与正常对照组的40例健康受试者进行比较分析。结果:AMI组血清Hcy、hs-CRP、Cys-C水平均显著高于正常对照组,差异均有统计学意义(P<0.05);且AMI组血清Hcy、hs-CRP、Cys-C两两之间均呈正性显著相关。结论:检测AMI患者血清Hcy、hs-CRP、Cys-C水平对患者病情评估及治疗措施的选择具有重要的临床意义。     

急性脑梗死患者血清心肌酶学变化的临床意义及相关危险因素分析

目的：探讨急性脑梗死患者血清心肌酶学变化与预后的关系及导致急性脑梗死患者心肌酶学变化的相关危险因素。方法：回顾性分析临床及影像资料齐全且确诊的140例急性脑梗死患者（发病14天内）,根据有无血清心肌酶学升高分为血清心肌酶学升高的急性脑梗死组A组（43例）,血清心肌酶学正常的急性脑梗死组B组（97例）,应用美国国立卫生研究院卒中量表评分（NIHSS）比较两组神经功能缺损情况,并对两组病人血清心肌酶学（包括天冬氨酸氨基转移酶（AST）、肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、乳酸脱氢酶（LDH）、血糖、血脂、纤维蛋白原和血压等结果进行分析。结果：A组（31%）患者血清心肌酶学均增高,与B组比较均有显著性差异（P〈0.01）;发病后1天A、B两组患者临床神经功能缺损程度评分无显著性差异,发病后4、8、10天A、B两组患者临床神经功能缺损程度评分有显著性差异（P〈0.01）;A组高血压、糖尿病与B组比较有显著性差异（P〈0.05）;而血脂及纤维蛋白原两组比较无显著性差异。结论：急性脑梗死患者血清心肌酶学升高者预后不良;高血压、糖尿病是急性脑梗死患者血清心肌酶学升高的相关危险因素。     

急性脑梗死患者血清心肌酶学变化的临床意义及相关危险因素分析

目的:探讨急性脑梗死患者血清心肌酶学变化与预后的关系及导致急性脑梗死患者心肌酶学变化的相关危险因素。方法:回顾性分析临床及影像资料齐全且确诊的140例急性脑梗死患者(发病14天内),根据有无血清心肌酶学升高分为血清心肌酶学升高的急性脑梗死组A组(43例),血清心肌酶学正常的急性脑梗死组B组(97例),应用美国国立卫生研究院卒中量表评分(NIHSS)比较两组神经功能缺损情况,并对两组病人血清心肌酶学(包括天冬氨酸氨基转移酶(AST)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)、血糖、血脂、纤维蛋白原和血压等结果进行分析。结果:A组(31%)患者血清心肌酶学均增高,与B组比较均有显著性差异(P<0.01);发病后1天A、B两组患者临床神经功能缺损程度评分无显著性差异,发病后4、8、10天A、B两组患者临床神经功能缺损程度评分有显著性差异(P<0.01);A组高血压、糖尿病与B组比较有显著性差异(P<0.05);而血脂及纤维蛋白原两组比较无显著性差异。结论:急性脑梗死患者血清心肌酶学升高者预后不良;高血压、糖尿病是急性脑梗死患者血清心肌酶学升高的相关危险因素。     

ST段抬高型心肌梗死患者血钾水平与原发性恶性室性心律失常的相关研究

目的:探讨ST段抬高型心肌梗死(STEMI)患者与冠状动脉造影阴性的对照组血钾水平以及低血钾发病率的差异;探讨STEMI患者中原发性恶性室性心律失常组和非原发性恶性室性心律失常组血钾水平的差异.方法:选取2007年1月至2009年11月间STEMI并行直接经皮冠状动脉介入术(直接PCI)患者371例,其中男303例,女68例,平均年龄(56.1±11.7)岁.同时选取冠状动脉造影阴性患者(对照组)161例,其中男性131人,女性30人,平均年龄(56.8±10.3)岁.两组基线资料无显著性差异.将血钾含量＜3.5mmol/l定义为低血钾,比较2组间血钾含量及低血钾发病率.根据直接PCI之前是否发生原发性室颤和持续性室速,将STEMI患者分为原发性恶性室性心律失常组和非原发性恶性室性心律失常组,本组数据所指原发性恶性室性心律失常仅包括直接PCI之前发生的原发性室颤和持续性室速,其中原发性室颤24例,持续性室速11例.比较2组间血钾水平.结果:血钾含量STEMI患者(3.81±0.49)低于对照者(4.03+0.41)mmol/L,差异有统计学意义(t=5.08,P＜0.001).低血钾发病率STEMI(22.6%)高于对照者(6.83%),差异有统计学意义(X2=19.13,P＜0.001).STEMI患者中原发性恶性室性心律失常组和非原发性恶性室性心律失常组的血钾水平差异无统计学意义.结论:STEMI患者急性期存在血钾的下降,我们需要积极纠正低血钾,但低血钾与原发性恶性室性心律失常有无必然联系仍需更深入的研究.     

Likelihood and Predictors of ST-Elevation in Patients Hospitalized for Myocardial Infarction

Importance

Emergency treatment options in myocardial infarction are guided by presence or absence of ST-elevations in electrocardiography. Occurrence and factors associated with ST-presentation in different population groups are however inadequately known.

Objective

To determine likelihood and patient features associated with ST-elevations in myocardial infarction.

Design

Nationwide registry study including 22 hospitals with angiolaboratory during an eight year period in Finland.

Setting

Hospitalized care.

Participants

68,162 consecutive patients aged ≥30 with myocardial infarction.

Measures

Likelihood and patient features associated with presence of ST-elevations.

Results

Myocardial infarction presented with ST-elevation in 37.5% (CI 37.0–37.9%) and without in 62.5% (CI 61.9–63.1%) of patients, p<0.0001. Majority of patients aged 30–59 years with myocardial infarction had ST-elevation, but among octogenarians ST-elevations were present in only 24.7%. Presence of ST-elevations decreased with age by estimated 15.6% (CI 15.0–16.2%) per 10 year increase (p<0.0001). Men aged 40–79 years had significantly higher rate for ST-elevation myocardial infarction compared to women. Sex-based difference in presentation of myocardial infarction declined with increasing age. Overall, men had a 13% (CI 11–15%, p<0.0001) higher relative risk for ST-elevations compared to women when adjusted for age and co-morbidities. Diabetes, atrial fibrillation, peripheral or cerebral artery disease, chronic pulmonary disease, malignancy, and renal insufficiency were associated with absence of ST-elevations in myocardial infarction in multivariate analysis.

Conclusions and Relevance

Myocardial infarction presents with ST-elevations more commonly in men. Presence of ST-elevations decreases with increasing age. Diabetes, atrial fibrillation, peripheral or cerebral artery disease, chronic pulmonary disease, malignancy, and renal insufficiency are associated with absence of ST-elevations in myocardial infarction. These findings may help to predict likelihood of ST-elevations in a patient with myocardial infarction.     

急性心肌梗死伴新发束支传导阻滞的临床意义

目的:观察急性心肌梗死伴新发左、右束支传导阻滞的临床特点,评价束支阻滞对急性心肌梗死预后的影响。方法:对上海交通大学附属第一人民医院心内科重症监护室2010年1月1日到12月31日收治的197例急性心肌梗死患者的病历资料进行回顾性分析,根据束支传导阻滞有无及类型分为左束支传导阻滞组(12例),右束支传导阻滞组(19例)和对照组(无束支传导阻滞的急性心梗,166例)。分析和比较三组患者的基线资料,心梗部位、Killip分级、恶性室性心律失常、左室射血分数LVEF、病变血管数量、梗死相关冠脉、住院天数及病死率、实验室检查(BNP,心肌损伤标志物峰值)。结果:LBBB组AMI患者的恶性心律失常发生率明显高于对照组(P=0.007),LVEF明显低于RBBB组和对照组(P值分别为0.020、0.045),梗死相关动脉以LAD多见。结论:急性心梗伴束支传导阻滞往往提示病情严重,预后不良,急性心梗合并左束支阻滞较合并右束支阻滞病情更严重。     

低分子肝素联合丹参注射液治疗急性心肌梗死的临床研究

目的:观察低分子肝素联合丹参注射液治疗急性ST段抬高型心肌梗死的临床疗效及安全性。方法:按照随机原则将78例急性心肌梗死患者分成两组,在常规溶栓治疗的基础上,其中对照组39人采用低分子肝素治疗,治疗组患者在对照组治疗的基础上给予丹参注射液治疗,对两组临床费用、住院时间和冠脉再通进行评价。结果:治疗组的临床费用、住院时间和冠脉再通与对照组相比,有统计学差异(P0.05)。结论:低分子肝素联合丹参注射液治疗急性心肌梗死的临床疗效确切,值得临床推广。     

C 反应蛋白、白细胞计数与脑梗死体积及近期预后的关系

目的:研究血清C反应蛋白水平、白细胞计数与急性脑梗死患者的梗死灶体积大小以及预后的关系。方法:检测70例急性脑梗死患者(CI组)、64例腔隙性脑梗死患者(LCI组)和80例健康人(对照组)的血浆CRP水平,并进行白细胞计数。在CI及LCI组人院当天和4周时进行临床神经功能缺损程度评分(NDS)评定以判断预后。结果:CI组血浆CRP水平高于LCI组及对照组(P<0.01),LCI组高于对照组(P<0.01);CI组白细胞计数高于LCI组及对照组(P<0.01),LCI组高于对照组(P<0.05);血浆CRP水平及白细胞计数正常组患者住院4周时显著进步和进步的比率明显高于血浆CRP水平及白细胞计数异常组(均P<0.01),而无变化和死亡的比率明显低于异常组(均P<0.01)。结论:ACI患者血浆CRP水平和白细胞计数均明显升高;脑梗死急性期血清CRP水平、白细胞计数可能与脑梗死患者梗死体积大小以及近期预后有密切的关系。     

T波峰-末间期对急性心肌梗死并发室性心律失常的预测价值

目的:探讨T波峰-末间期(Tp-Te间期)和Tp-Te间期离散度(Tp-Ted)对急性心肌梗死并发室性心律失常的预测价值。方法:选择我院2013年5月至2014年5月收治的140例确诊急性ST段抬高型心肌梗死(STEMI)患者,按照心律失常类型分为室性心动过速组,室性早搏组以及无室性心律失常组。分析并比较各组患者心电图Tp-Te间期及Tp-Ted的变化情况。结果:急性期FPG、Tp-Te、Tp-Ted高于恢复期,差异有统计学意义(P0.05);急性期与恢复期之间TG、CHOL、LDL-C、K+、Na+水平差异无统计学意义(P0.05)。无室性心律失常组与室性心动过速组及室性早搏组比较,Tp-Te和Tp-Ted更低,差异有统计学意义(P0.05);室性早搏组和室性心动过速组比较,Tp-Te和Tp-Ted更低,差异有统计学意义(P0.05)。结论:Tp-Te间期和Tp-Ted可用于区分急性心肌梗死患者室性心律失常类型。     

Specificity of Serum Creatine Kinase Isoenzymes in Diagnosis of Acute Myocardial Infarction

A study of the diagnostic value of serum creatine kinase (CK) isoenzymes showed that MB isoenzyme, which characterizes heart tissue, was a specific and sensitive indicator of acute myocardial infarction. In cases where the clinical picture was complicated by ventricular tachycardia, severe congestive failure, shock, or resuscitation procedures heart, liver, and muscle enzymes were increased. There was also an increase in lactate dehydrogenase isoenzyme values in these cases; indeed, the only enzyme test that correlated well with electrocardiographic and necropsy findings was the MB isoenzyme.     

大鼠急性心肌梗死模型的制备及对肌钙蛋白T的影响

目的探讨建立大鼠急性心肌梗死（AMI）模型的方法,研究心肌梗死大鼠血浆中肌钙蛋白T（cTn-T）的动态变化。方法大鼠经结扎左冠状动脉前降支造成心肌梗死,建立稳定的心肌梗死模型;分别在结扎后31 h、48 h、69 h、168 h检测cTn-T含量和计算心肌梗死重量指数。结果成功制备心肌梗死大鼠模型,并对常规技术进行改进,降低动物死亡率。大鼠左冠状动脉结扎31 h、48 h模型组与假手术组cTn-T含量差异极显著（P〈0.001）;各时间点心肌梗死重量指数比较,差异极显著（P〈0.001）。cTn-T值与梗死重量指数呈显著性正相关（r=0.90,P〈0.01）。结论结合大鼠心肌梗死程度进一步佐证了模型制备较成功。cTn-T表现出特异性和敏感性,并在31 h最接近达峰时间,有早期诊断心肌梗死的价值,也可作为判断AMI时心肌梗死程度和预后的参考指标。     

血清CREG蛋白在急性心肌梗死早期的表达研究

目的：探讨血清中CREG蛋白在急性心肌梗死发作早期的表达情况,尝试为临床心肌缺血的极早期诊断提供一种新的血清标志分子。方法：在2010年6月至2010年11月期间,入选在沈阳军区总医院心内科住院治疗的急性ST段抬高型心肌梗死患者50例及非AMI对照50例,于AMI组胸痛发作后的不同时间点采血测定CK、CK—MB、LDH和cTnT,同时应用Westem blot技术测定血清中CREG蛋白的含量,并与对照组比较。结果：AMI组发病72小时内的血清中CREG蛋白表达均较对照组有不同程度的增高（P〈0．05）。胸痛开始2h内,AMI组血清中CREG的含量即明显增高,其在2h、4h及6h的含量显著高于对照组（P〈0．001）。在胸痛已经发作2小时内,两组间血清cTnT、CK、CK-MB及LDH水平比较无统计学意义（P〉0．05）。结论：CREG在AMI患者血清中的表达增高．其在血清中表达时间早于cTNT及CK-MB。     

血清CREG蛋白在急性心肌梗死早期的表达研究

目的:探讨血清中CREG蛋白在急性心肌梗死发作早期的表达情况,尝试为临床心肌缺血的极早期诊断提供一种新的血清标志分子。方法:在2010年6月至2010年11月期间,入选在沈阳军区总医院心内科住院治疗的急性ST段抬高型心肌梗死患者50例及非AMI对照50例,于AMI组胸痛发作后的不同时间点采血测定CK、CK-MB、LDH和cTnT,同时应用Western blot技术测定血清中CREG蛋白的含量,并与对照组比较。结果:AMI组发病72小时内的血清中CREG蛋白表达均较对照组有不同程度的增高(P<0.05)。胸痛开始2h内,AMI组血清中CREG的含量即明显增高,其在2h、4h及6h的含量显著高于对照组(P<0.001)。在胸痛已经发作2小时内,两组间血清cTnT、CK、CK-MB及LDH水平比较无统计学意义(P>0.05)。结论:CREG在AMI患者血清中的表达增高,其在血清中表达时间早于cTNT及CK-MB。     

Profiles of Serum Cytokines in Acute Drug-Induced Liver Injury and Their Prognostic Significance

Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the United-States. The aim of the study was to describe serum immune profiles associated with acute DILI, to investigate whether there are profiles associated with clinical features or types of DILI and/or with prognosis, and to assess temporal changes in levels. Twenty-seven immune analytes were measured in the sera of 78 DILI subjects in the Drug-Induced Liver Injury Network (DILIN) and compared with 40 healthy controls. Immune analytes (14 cytokines, 7 chemokines and 6 growth factors) were measured by BioPlex multiplex ELISA at DILI onset and after 6 months. A modeling process utilizing immune principles was used to select a final set of variables among 27 immune analytes and several additional clinical lab values for prediction of early death (within 6 months of DILI onset). Nineteen of the 27 immune analytes were differentially expressed among healthy control, DILI onset and 6-month cohorts. Disparate patterns of immune responses, especially innate and adaptive cellular (mostly TH17) immunity were evident. Low values of four immune analytes (IL-9, IL-17, PDGF-bb and RANTES) and serum albumin are predictive of early death [PPV = 88% (95% CI, 65%-100%), NPV = 97% (95% CI, 93%-100%), accuracy = 96% (95% CI, 92%-100%)].

Conclusions

Acute DILI is associated with robust and varying immune responses. High levels of expression of cytokines associated with innate immunity are associated with a poor prognosis, whereas high levels of expression of adaptive cytokines are associated with good long-term prognosis and eventual recovery. Serum immune analyte profiles at DILI onset appear to be of prognostic, and perhaps, diagnostic significance.     

The Effect of c-fos on Acute Myocardial Infarction and the Significance of Metoprolol Intervention in a Rat Model

Over-expression of c-fos may play a role in some diseases. Research pertaining to the expression of c-fos in acute myocardial ?nfarction (AMI) is rare, and the detailed role of c-fos in AMI has not been reported. Therefore, the purpose of this project was to elucidate the detailed effect of c-fos on AMI rats and evaluate the effect of a metoprolol intervention. An AMI rat model was established for the purposes of this study. The expression of c-fos in AMI was evaluated via immunohistochemical analysis and in situ hybridization. Simultaneously, we investigated the effect of c-fos on AMI rats via medicinal treatment with c-fos monoclonal antibody, isoproterenol, and metoprolol. Positive c-Fos protein expression and c-fos mRNA expression in cardiomyocytes were increased at 1, 3, 7, and 10 days after ligation in AMI rats compared with a sham-operated group. Peak expression occurred at 3 days after ligation. The weight percentage fraction of infarct size was decreased in rats treated with c-fos monoclonal antibody compared with the control normal saline treatment group. The weight percentage fraction of infarction size was increased after c-fos was increased via the administration of isoproterenol. c-Fos protein expression and the infarct size in rats treated with metoprolol were also decreased compared with the control normal saline treatment group. The results showed that c-fos expression rapidly increased after coronary ligation; c-fos plays an important role in myocardial lesions and is likely to be involved in the pathogenesis of AMI as well. Metoprolol can inhibit the expression of c-fos and has a positive therapeutic effect on rats after AMI; the involvement effect of metoprolol on myocardial infarction might be correlated with its effect on the inhibition of c-fos.     

渐进性肌肉放松训练对急性心肌梗死病人焦虑状态的影响

为了确定渐进性肌肉放松对急性心肌梗死患者焦虑情绪是否有缓解作用,本研究选取2016年4月至2019年4月期间在曲靖市第一人民医院心内科治疗的患者274例作为研究对象,随机分为对照组和观察组,每组137例,平均年龄(53.27±10.3)岁。对照组在治疗期间给予常规护理,而观察组在常规护理的基础上给予渐进性肌肉放松治疗。放松治疗每天2次,每次10组,一周4天,共治疗4周。分别于患者入院48 h和治疗后1个月对患者的血压、心率、并发症以及焦虑水平进行记录评估。研究显示,入院治疗1个月后,患者的血压、心率均有所下降,但无统计学差异;相较于对照组,观察组的并发症发病患者均明显下降(p<0.05);此外,患者入院时均有不同程度的焦虑情绪,经过一个月的治疗后患者的焦虑评分均明显下降,且在观察组中焦虑得分更显著低于对照组(p<0.05)。本实验在较大的临床样本中证实渐进性肌肉放松训练能明显降低患者的焦虑情绪并有助于降低患者并发症,能在治疗急性心肌梗死患者时提供较大帮助,为临床应用放松训练辅助治疗心肌梗死提供了较为可靠的实验证据,有重要的实用价值。     

Effects of Intra-Aortic Balloon Counterpulsation Pump on Mortality of Acute Myocardial Infarction

Background

Several randomized controlled trials (RCTs) have evaluated the effect of intra-aortic balloon counterpulsation pump(IABP) on the mortality of acute myocardial infarction (AMI).

Objectives

To analyze the relevant RCT data on the effect of IABP on mortality and the occurrence of bleeding in AMI.

Data Sources

Published RCTs on the treatment of AMI by IABP were retrieved in searches of Medline, EMBASE, Cochrane and other related databases. The last search was conducted on July 20, 2014.

Study Eligibility Criteria

Randomized clinical trials comparing IABP to controls as treatment for AMI.

Participants

Patients with AMI.

Synthesis Methods

The primary endpoint was mortality, and the secondary endpoint was bleeding events. To account for to heterogeneity, a random-effects model was used to analyze the study data.

Results

Ten trials with a total population of 973 patients that were included in the analysis showed no significant difference in 2-month mortality between the IABP and the control groups. The 6-month mortality in the IABP group was not significantly lower than in the control group in the four RCTs that enrolled 59 AMI patients with CS. But in the four that enrolled AMI 66 patients without CS, the data showed opposite conclusion.

Conclusions

IABP cannot reduce within 2 months and 6–12 months mortality of AMI patients with CS as well as within 2 months mortality of AMI patients without CS, but can reduce 6–12 months mortality of AMI patients without CS. In addition, IABP can increase the risk of bleeding.     

扶正化瘀胶囊对心肌梗死大鼠心肌纤维化的影响

目的：急性心肌梗死是危害人类健康的重大疾病之一,心肌梗死后心肌纤维化是造成心脏结构破坏、心功能下降、心律失常发生、心衰甚至猝死的微观病理机制。防治心肌纤维化是当前医学研究的重点和热点。本研究主要探讨扶正化瘀胶囊对心肌梗死大鼠心肌纤维化的干预作用。方法：大鼠随机分为假手术组、模型组、扶正化瘀胶囊组和卡托普利组,采用结扎冠状动脉前降支的方法建立心肌梗死模型,假手术组只穿线,不结扎。于造模成功后第10天开始给予相应药物治疗2个月。治疗结束后,检测左心室梗死范围和心肌胶原含量。结果：与假手术组比较,模型组、扶正化瘀胶囊组和卡托普利组的非梗死区面积显著减小（P〈0.01）。与模型组比较,扶正化瘀胶囊组和卡托普利组的梗死区面积和梗死百分比显著减小（P〈0.05,P〈0.01）。在心肌胶原表达上,与假手术组比较,模型组和扶正化瘀胶囊组胶原含量显著增加（P〈0.01）。与模型组比较,卡托普利组和扶正化瘀胶囊组胶原含量显著降低（P〈0.05,P〈0.01）。结论：扶正化瘀胶囊能够改善心肌缺血,缩小心肌梗死范围,抑制心肌胶原表达,除能用于肝纤维化的治疗外,还能用于防治心肌梗死后的心肌纤维化。